None
Quote | BridgeBio Pharma Inc. (NYSE:BBIO)
Last: | $ |
---|---|
Change Percent: | -0.55% |
Open: | $35.05 |
Close: | $34.65 |
High: | $35.07 |
Low: | $33.77 |
Volume: | 249,717 |
Last Trade Date Time: | 02/12/2020 04:42:27 pm |
News | BridgeBio Pharma Inc. (NYSE:BBIO)
2024-05-14 11:24:32 ET More on BioNTech, Moderna, etc. BioNTech SE 2024 Q1 - Results - Earnings Call Presentation BioNTech SE (BNTX) Q1 2024 Earnings Call Transcript Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks Moderna announces del...
PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will pres...
Message Board Posts | BridgeBio Pharma Inc. (NYSE:BBIO)
Subject | By | Source | When |
---|---|---|---|
Offering comign | Pt3 | investorshub | 03/06/2023 4:47:20 PM |
BridgeBio Announces Positive Phase 2 Cohort 5 Results | 02opida | investorshub | 03/06/2023 4:21:16 PM |
BridgeBio Announces Positive Phase 2 Cohort 5 Results | subslover | investorshub | 03/06/2023 1:34:59 PM |
Recent Trades - Last 10 of 1063 | 02opida | investorshub | 12/08/2022 4:21:10 PM |
volume will start to pickup | 02opida | investorshub | 08/09/2022 6:09:28 PM |
News, Short Squeeze, Breakout and More Instantly...
BridgeBio Pharma Inc. Company Name:
BBIO Stock Symbol:
NYSE Market:
PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biop...
PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will pres...
- In a pre-specified Cochran-Mantel-Haenszel sensitivity analysis applied to the entire intention-to-treat (ITT) population of the study (N=632), acoramidis significantly reduced all-cause mortality (p=0.04), with no safety signals of potential clinical concern - Among ATTRibute-CM part...